Latest news with #Avicel
&w=3840&q=100)
Business Standard
30-05-2025
- Business
- Business Standard
Astonea Labs IPO allotment today; check latest GMP, steps to verify status
Astonea Labs IPO allotment status: The basis of allotment of shares for Astonea Labs is expected to be finalised today, Friday, May 30, 2025. The initial public offering (IPO) of Astonea Labs, which closed for subscription on Thursday, May 29, received a muted response from investors, with the offering being oversubscribed by nearly 1.8 times. Once the allotment is finalised, investors can check their status on the official websites of the BSE and Kfin Technologies, the registrar for the Astonea Labs IPO. Alternatively, investors can also follow these direct links to check the Astonea Labs IPO allotment status online: Check Astonea Labs IPO allotment status on BSE: Check Astonea Labs IPO allotment status on Kfin Technologies: Astonea Labs IPO details The SME offering, valued at around ₹37.67 crore, comprises an entirely fresh issue of 2.79 million equity shares with no offer for sale (OFS) component. The public issue was open for subscription from Tuesday, May 27, 2025, to Thursday, May 29. Astonea Labs IPO was available at the price band of ₹128 to ₹135 per share, with a lot size of 1,000 shares. Kfin Technologies serves as the registrar, while Oneview Corporate Advisors acts as the sole book-running lead manager for the offering. According to the RHP, the company aims to utilise the issue proceeds for funding of expenses proposed to be incurred towards registration in Bolivia, South America; purchase and installation of plant and machineries for ointment production for the purpose of export in accordance with the international standards and protocols, on the second floor of the existing premises; advertising, marketing and brand building; investment in procuring hardware and software and funding of working capital requirements. The remaining funds will be used for general corporate purposes. Check Blue Water Logistics IPO allotment status About Astonea Labs Incorporated in 2017, Astonea Labs is a contract manufacturer of pharmaceutical and cosmetic products for companies both within India and internationally. The company manufactures and markets a variety of pharmaceutical and cosmetic products, including antibiotics, anti-cold medicines, antihistamines, and treatments for diabetes, heart, gynecological issues, infections, and more. The company offers skin, tooth, and hair care products in forms like gels, creams, and serums, and also trades packaging and raw materials for pharmaceutical and cosmetic industries, meeting industry standards. The company engages in contract manufacturing of pharmaceutical and cosmetic products, markets its own brands Glow Up and Regero, plans to launch Avicel, and exports to countries like Iraq and Yemen.
Business Standard
26-05-2025
- Business
- Business Standard
Astonea Labs Ltd plans to raise up to Rs. 37.67 crore from Public Issue; IPO opens on May 27
PNN New Delhi [India], May 26: Haryana based pharmaceutical and cosmetic products manufacturer, Astonea Labs Ltd is planning to raise Rs. 37.67 crore from its SME public issue. The company has received approval to launch its public issue on BSE SME Platform. The public issue open for subscription on May 27 and closes on May 29. Oneview Corporate Advisors Private Limited is the lead manager of the issue. Company plans to issue 27.90 lakh Equity shares of Rs. 10 face value at a price band of Rs. 128- Rs. 135 per share; Shares to list on BSE SME Highlights:- * Fresh Public issue of Rs. 37.67 crore opens for subscription from May 27 to May 29 * Minimum lot size for application is 1000 shares; Minimum IPO application amount at the higher side of this issue is Rs. 1.35 lakh * Funds raised through the issue will be used for Expenses, Business & Capacity Expansion, Advertising & Marketing, Investment in procuring hardware and software and Funding Capital Expenditure * For FY23-24 company reported revenue of Rs. 80.29 crore and Net Profit of Rs. 3.81 crore * As on 31 March 2024, ROE at 37.86%, ROCE at 22.95% and RoNW at 31.83%. * Oneview Corporate Advisors Private Limited is the lead manager of the issue. The initial public offering of Rs. 37.67 crore comprises of a fresh issue of 27.90 lakh equity shares of face value Rs. 10 each with a price band of Rs. 128 to Rs. 135 per share. Out of the fresh issue of Rs. 37.67 crore, company plans to utilize Rs. 1.29 crore towards funding of expenses proposed to be incurred towards registration in Bolivia, South America while Rs. 5.2 crore will be used towards purchase and installation of plant and machineries for ointment production for the purpose of export in accordance with the international standards and protocols. Company also plans to utilize Rs 4.95 crore for advertising, marketing and brand building, Rs. 68 lakh for investment in procuring hardware and software and Rs. 19.75 crore for working capital requirements. Minimum lot size for the application is 1000 shares which translates in to minimum investment of Rs. 1.35 lakh per application on higher side of issue. The retail quota is 35%, QIB is 50%, and HNI is 15%. Incorporated in 2017, Astonea Labs Ltd. is engaged in contract manufacturing of pharmaceutical and cosmetic products for companies both within India and internationally. The company manufactures and markets a variety of pharmaceutical and cosmetic products, including antibiotics, anti-cold medicines, antihistamines, and treatments for diabetes, heart, gynecological issues, infections, and more. The company offers skin, tooth, and hair care products in forms like gels, creams, and serums, and also trades packaging and raw materials for pharmaceutical and cosmetic industries, meeting industry standards. The company engages in contract manufacturing of pharmaceutical and cosmetic products, markets its own brands "Glow Up" and "Regero," plans to launch "Avicel," and exports to countries like Iraq and Yemen. For FY23-24 ended March 2024, the company reported revenue of Rs80.29 crores in 2024 against Rs67.26 crore in 2023. The company reported profit of Rs3.81 crores in 2024 against profit of Rs0.67 crores in 2023, with a healthy EBITA margin of 14.60% and PAT margin of 4.75%. For the nine months ended December 2024, company reported total revenue of Rs. 69.55 crore and Net Profit of Rs. 4.10 crore. As on 31st March 2024, ROE of the company was at 37.86%, ROCE at 22.95% and RONW at 31.83%.
